A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Phase 3Recruiting
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 531 (estimated)
- Start date
- 2 Jul 2026
- Primary completion
- Sep 2030 (estimated)
- Study completion
- 1 Sep 2030
- Last update posted
- 23 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- ABBV-706 Drug
- Topotecan Drug
- Lurbinectedin Drug
- Amrubicin Drug
Conditions and primary outcome
- Small Cell Lung Cancer
Primary outcome
Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (Up to approximately 24 months); Overall Survival (OS) (Up to approximately 28 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07365241.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07365241 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.